Nicoletta Colombo

Also affiliated with University of Milano-Bicocca

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

4in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 4 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 19 papers. Top paper: “MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum”.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Journal of Clinical Oncology(2020)10.1200/jco.20.01164

N/A

4.6DataRank · unranked

153 citations

Rachel N. Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero +25 more

Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup

The Lancet Oncology(2022)10.1016/s1470-2045(22)00139-5

N/A

2.8DataRank · unranked

144 citations

Antonio González-Martı́n, Domenica Lorusso, Charlie Gourley, Mansoor Raza Mirza, Jean‐Emmanuel Kurtz +73 more

A Phase 2 study of prexasertib (LY2606368) in platinum resistant or refractory recurrent ovarian cancer

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.09.019

N/A

1.6DataRank · unranked

67 citations

Jungmin Lee, Bo Gao, Rowan Miller, Jung‐Yun Lee, Nicoletta Colombo +8 more

Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup

Journal of Clinical Oncology(2009)10.1200/jco.2008.19.1684

N/A

0.984DataRank · unranked

706 citations

Mark F. Brady, William P. McGuire, Peter G. Harper, David S. Alberts, D. Ennis +13 more

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0621

N/A

0.949DataRank · unranked

22 citations

Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza +25 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005919

N/A

0.812DataRank · unranked

25 citations

Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley +16 more

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Journal of Clinical Oncology(2025)10.1200/jco-25-00112

N/A

0.722DataRank · unranked

36 citations

Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew R. Clamp +20 more

Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 Trial

JCO Precision Oncology(2023)10.1200/po.22.00258

N/A

0.612DataRank · unranked

58 citations

Jessica Brown, Alan Barnicle, Jonathan Wessen, Pierre Lao-Sirieix, Steven W. Criscione +16 more

In-house testing for homologous recombination repair deficiency (HRD) testing in ovarian carcinoma: a feasibility study comparing AmoyDx HRD Focus panel with Myriad myChoiceCDx assay

Pathologica(2022)10.32074/1591-951x-791

N/A

0.584DataRank · unranked

48 citations

Ilaria Betella, Alberto Ranghiero, Elena Guerini-Rocco, Giulio Bonaldo, Alessandra Rappa +4 more

High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk‐oriented consolidation: A critical review of a 10‐year, single‐center experience in younger, non M3 AML patients

American Journal of Hematology(2016)10.1002/ajh.24391

N/A

0.477DataRank · unranked

23 citations

Paola Minetto, Marino Clavio, Maurizio Miglino, Carmen Di Grazia, Filippo Ballerini +11 more

Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice

European Journal of Cancer(2023)10.1016/j.ejca.2023.03.015

N/A

0.434DataRank · unranked

17 citations

Nicoletta Colombo, Antonio Casado, Alessandro D. Santin, Émeline Colomba, David S. Miller +14 more

884TiP AtTEnd/ENGOT-en7: A multicenter phase III double-blind randomized controlled trial of atezolizumab in combination with paclitaxel and carboplatin in women with advanced/recurrent endometrial cancer

Annals of Oncology(2020)10.1016/j.annonc.2020.08.2090

N/A

0.269DataRank · unranked

5 citations

Yoland Antill, M.P. Barretina Ginesta, Kenichi Harano, Emma Hudson, Frederik Marmé +8 more

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775

Journal for ImmunoTherapy of Cancer(2026)10.1136/jitc-2025-013713

N/A

0.104DataRank · unranked

1 citations

Nicoletta Colombo, Antonio Casado, Alessandro D Santin, Emeline Colomba, David S. Miller +25 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more

Endometrial carcinosarcoma

International Journal of Gynecological Cancer(2022)10.1136/ijgc-2022-004073

N/A

0DataRank · unranked

95 citations

Isabelle Ray‐Coquard, Nicole Concin, Natalie Y.L. Ngoi, Philippe Morice, Giuseppe Caruso +35 more

Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Annals of Oncology(2022)10.1016/j.annonc.2022.05.009

N/A

0DataRank · unranked

636 citations

Tjalling Bosse, Carien L. Creutzberg, Gonzalo Giornelli, Philipp Harter, Florence Joly +7 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more